RIYADH, November 10, 2025 (Saudi Arabia Breaking News) – The Saudi Food and Drug Authority (SFDA) has approved the registration of Pemazyre (Pemigatinib) as a monotherapy for adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement who have progressed after at least one prior line of systemic therapy. Pemazyre functions by inhibiting FGFR2 receptors located on the surface of certain cancer cells.
